Discovered that ruxolitinib competitively inhibits the transportation purpose of ABCB1, and more importantly, the expression of ABCB1 plays a task in analyzing the efficacy of ruxolitinib within a cell line As well as in Key human T cells [97]. The impact of ruxolitinib on MDR mediated by ABC drug transporters https://smedleyu470uqw3.dm-blog.com/profile